Close Menu

NEW YORK (GenomeWeb) – Veracyte said yesterday that it has expanded the early-access program (EAP) for its Envisia Genomic Classifier for differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs).

Veracyte launched the EAP in May to provide advance access to the test in anticipation of a nationwide launch in 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.